Nebula Genomics

Blockchain-enabled genomic data sharing and analysis platform

[Short general description]: Nebula Genomics will leverage blockchain technology to eliminate the middleman and empower people to own their personal genomic data. Nebula is using blockchain technology to construct a platform that lets customers reap the benefits of making their genetic information available to researchers, while maintaining their privacy.


[Main problems tackled]: Nebula’s main aim is described through their motto: “Understand your genome. Help cure diseases. Own your data. Powered by blockchain”.

The Nebula model eliminates personal genomics companies as middlemen between data owners and data buyers. Instead, data owners can acquire their personal genomic data from Nebula sequencing facilities or other sources, join the Nebula blockchain-based, peer-to-peer network and directly connect with data buyers. How?

1) Lower sequencing costs - nebula reduces effective sequencing costs 

2) Enhanced data protection - data is protected through multiple mechanisms

3) Efficient data acquisition -  efficiently acquire large genomic datasets.

4) Big data ready - primed for the forthcoming explosion of genomic data.


[Main contribution proposal]: The Nebula economy - will be driven by three forces: technological advancement, industry needs, and the consumer market. First, as DNA sequencing technology advances, the costs of human genome sequencing will further decrease and more people will sequence their genomes. Second, industry demand for genomic data will attract more people to join the Nebula network and share their data, thereby further increasing the value of the network and resulting in even more demand. Third, genomic data growth will enable medical research that will expand our knowledge of human genetics, thereby enabling better interpretation of individual human genomes and ultimately attracting more people to sequence their genomes.



1) Nebula network - The Nebula network is built on the Blockstack ( platform and the Ethereum-derived Nebula blockchain

2) Genetic data generation - samples will be sequenced using next-generation DNA sequencing

3) Phenotypic data generation - buyers will be able to send survey questions to data owners. Importantly, surveys can be designed as chains of interdependent questions that will reveal the true phenotypes even if the survey participants are incentivized to give false responses to make their data appear more valuable

4) External data aggregation - Genomic data that was not generated at Nebula sequencing facilities can be offered on the Nebula network as wel

5) Data storage - Data storage and access control will be implemented using the Blockstack platform for decentralized apps.

6) Personal genome interpretation - data owners will able to interpret their personal genomic data without sharing it with any third party. 

7) Secure computations - Genomic and phenotypic data will be analyzed using the Arvados ( open source bioinformatics platform, 

8) Data owner protection - data owners may have to reveal their phenotypic information in plaintext. For instance, a data buyer who considers subsidizing the sequencing of a data owner will request to see the unencrypted phenotypic data.

9) Payments - The prices will be in Nebula tokens and will decrease at an exponential rate as DNA sequencing becomes cheaper

10) Third-party apps - Helix sequences customer samples and third party developers build apps that provide interpretation.

ICO Rating Analysis
Team Evaluation
5.00 / 5.00
Token Economics
4.00 / 5.00
Hype and media presence
3.00 / 5.00


Team - Founders:
Are the founders known? Do they have relevant experience and connections?
  • 1. Unknown people. No serious background information available.
  • 2. Partial information available, no relevant experience.
  • 3. Background information available, no relevant experience.
  • 4. Solid, relevant background and connections available.
  • 5. Solid, well known, experienced and well connected founders.
Team - Advisors:
What level of commitment, experience and connections do the advisers bring?
  • 1. No reputable advisors with relevant experience.
  • 2. Few advisors with little to no relevant experience.
  • 3. Advisers with relevant experience.
  • 4. Reputable advisors with relevant experience and connections.
  • 5. High profile highly experienced, well connected and committed advisors.
Product - Technology Layer:
Is the product innovative? Does it contribute to the blockchain ecosystem?
  • 1. No, the product is just a clone with no contribution.
  • 2. The product is a dapp with minimal interest and little contribution to the ecosystem.
  • 3. The product is a dapp, exchange or protocol addressing a real problem or need.
  • 4. Innovative product offering a solution to a high interest problem.
  • 5. Innovative protocol tackling critical problems of highest interest.
Product - Proof of concept:
Is the proof of concept comprehensive? Does it address a real problem or need?
  • 1. No, incoherent concept or no need for it.
  • 2. Difficult concept to understand, hardly any need or problem to solve.
  • 3. Clear concept which addresses a real problem.
  • 4. Clear, well thought concept which addresses a real problem of high interest.
  • 5. Exceptional proof of concept addressing a critical problem.
Product - MVP:
Has the concept been tested? Is there an MVP? How far is the launch?
  • 1. Untested concept.
  • 2. Initial tests, no MVP.
  • 3. MVP ready, Alpha launch.
  • 4. MVP ready, Beta launch.
  • 5. Fully working initial product.
Token Economics - Token utility:
Does the token have any utility? Is it a core function to the network?
  • 1. No, the token has no utility.
  • 2. Token has a limited, unclear utility.
  • 3. The token has some added, but not inherent value.
  • 4. The token is embedded in the network and has inherent value.
  • 5. The token has both inherent and added value and is embedded at the core of the network.
Token Economics - Network effect:
Are strong network effects built into the system? Are incentives aligned to encourage the growth of the network?
  • 1. No network effects built in.
  • 2. Minimal network effects, unclear incentives.
  • 3. Network effects and incentives present.
  • 4. Solid network effects with clear incentives due to inherent utility.
  • 5. Strong network effects, aligned incentives and high utility value.
Business Evaluation - Valuation:
Is the valuation reasonable ? Sufficient but not too high for the scope of the project?
  • 1. No, the valuation is ludicrous, the project could do with 1/10 of the sum.
  • 2. Valuation is higher than the project would need. Likely a money grab.
  • 3. Valuation is reasonable for the scope of the project.
  • 4. Valuation is modest for the caliber of the project.
  • 5. Valuation is impressively modest relative to the high caliber of the project.
Business Evaluation - Market potential:
What is the market potential? Does the project look like it could penetrate the market and conquer the world?
  • 1. No clear market potential.
  • 2. Limited market potential.
  • 3. Reasonable market and growth potential.
  • 4. Solid market and growth potential.
  • 5. Exceptional market and growth potential.
Business Evaluation - Competition:
Does the project have competition? How strong does it look relative to its competition?
  • 1. Awful position competing with many strong players.
  • 2. Weak position facing strong competition.
  • 3. Reasonable position facing strong competition.
  • 4. Solid position facing weak competition.
  • 5. Exceptional position, facing almost no competition.
Business Evaluation - Supply sold:
Does the team distribute a reasonable amount of the tokens so as to encourage create strong incentives and network effects?
  • 1. Negligible supply, greedy team.
  • 2. Small supply, poor incentives.
  • 3. Modest supply, weak incentives.
  • 4. Reasonable supply, responsible team.
  • 5. Large supply, solid inventive, committed team.
Business Evaluation - Vesting:
Does the team have a sufficient stake to have aligned incentives? Do they have a vesting schedule implemented?
  • 1. Large stake, no vesting.
  • 2. Small stakes, no vesting.
  • 3. Modest stakes, no vesting.
  • 4. Reasonable stakes, modest vesting.
  • 5. Solid stake, healthy vesting.
Hype and media presence:
Is the project present on social media and chats? Is there interest for it?
  • 1. No presence, negative image.
  • 2. Modest exposure and no interest.
  • 3. Reasonable exposure and modest interest.
  • 4. Solid exposure and high interest.
  • 5. Exceptional exposure, high interest and considerable hype.
Final Score


George Church
Dennis Grishin
Kamal Obbad
Armon Rahim
Growth Lead
Kevin Quinn


Mirza Cifric
Co-founder and Chief Executive Officer of Veritas Genetics
Preston Estep
Co-founder and Chief Scientific Officer of Veritas Genetics
Yining Zhao
Founding partner at Just; Co-founder at Veritas Genetics
Drew Volpe
Managing Partner at First Star Ventures
Joseph Urgo
Founder of District0x and
D. A. Wallach
Investor and advisor to companies like SpaceX, Ripple, Emulate, and Spotify


Published at
Nebula Genomics at BioData World West 2018
1 year ago
Nebula Genomics at MIT-CEIBS
1 year ago